Jyoti Nangalia
- Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 32
- Hematology top 1%
- Acute Myeloid Leukemia Research 21
- Chronic Myeloid Leukemia Treatments 13
- Multiple Myeloma Research and Treatments 3
- Rheumatology top 2%
- Eosinophilic Disorders and Syndromes 6
- Cancer Research top 10%
- Cancer Genomics and Diagnostics 10
- Molecular Biology top 10%
- Kruppel-like factors research 15
- Single-cell and spatial transcriptomics 4
- Co-authors
- Anthony R. GreenPeter J. CampbellAnna L. GodfreyJacob GrinfeldClaire HarrisonEmily MitchellNicholas WilliamsAdam J. Mead
- Cited by
- GeneticsHematologyRheumatology
- Partner nations
- United KingdomUnited StatesItaly
In The Last Decade
Jyoti Nangalia
46 papers receiving 1.7k citations
Hit Papers
Peers
Comparison fields: 5 of 83
- Genetics 1.1k
- Hematology 993
- Rheumatology 399
- Cancer Research 217
- Molecular Biology 830
Countries citing papers authored by Jyoti Nangalia
This map shows the geographic impact of Jyoti Nangalia's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jyoti Nangalia with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jyoti Nangalia more than expected).
Fields of papers citing papers by Jyoti Nangalia
This network shows the impact of papers produced by Jyoti Nangalia. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jyoti Nangalia. The network helps show where Jyoti Nangalia may publish in the future.
Co-authorship network
The 25 scholars most cited alongside Jyoti Nangalia, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2025 | 2 | |
| 2 | 2025 | 0 | |
| 3 | 2024 | 36 | |
| 4 | 2024 | 10 | |
| 5 | 2024 | 13 | |
| 6 | 2023 | 27 | |
| 7 | Life histories of myeloproliferative neoplasms inferred from phylogenies.breakdown → | 2022 | 148 |
| 8 | 2021 | 84 | |
| 9 | 2021 | 17 | |
| 10 | 2020 | 10 | |
| 11 | 2018 | 94 | |
| 12 | 2018 | 70 | |
| 13 | 2018 | 49 | |
| 14 | 2017 | 0 | |
| 15 | 2016 | 63 | |
| 16 | 2015 | 20 | |
| 17 | 2015 | 24 | |
| 18 | 2014 | 55 | |
| 19 | 2014 | 46 | |
| 20 | 2013 | 96 |
About Jyoti Nangalia
Jyoti Nangalia is a scholar working on Genetics, Hematology and Cancer Research, having authored 48 papers that have together received 1.7k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (32 papers), Acute Myeloid Leukemia Research (21 papers), Kruppel-like factors research (15 papers), Chronic Myeloid Leukemia Treatments (13 papers), Cancer Genomics and Diagnostics (10 papers), Eosinophilic Disorders and Syndromes (6 papers), Single-cell and spatial transcriptomics (4 papers) and Multiple Myeloma Research and Treatments (3 papers). The work is most often cited by research in Genetics (1.1k citations), Hematology (993 citations) and Rheumatology (399 citations). Jyoti Nangalia has collaborated with scholars based in United Kingdom, United States and Italy. Frequent co-authors include Anthony R. Green, Peter J. Campbell, Anna L. Godfrey, Jacob Grinfeld, Claire Harrison, Emily Mitchell, Nicholas Williams, Adam J. Mead, Alessandro M. Vannucchi and Luiza Moore.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.